idera
pharmaceuticals
present
tilsotolimod
data
esmo
virtual
congress
final
data
trial
advanced
melanoma
final
results
trial
refractory
solid
tumors
presented
abbvie
present
poster
combination
tilsotolimod
recurrent
metastatic
head
neck
squamous
cell
carcinoma
hnscc
idera
also
present
wainwright
annual
global
investment
conference
exton
globe
newswire
idera
pharmaceuticals
idera
nasdaq
idra
today
announced
final
data
trial
investigating
intratumoral
tilsotolimod
idera
investigational
receptor
agonist
presented
mini
oral
presentation
european
society
medical
oncology
esmo
virtual
congress
held
september
addition
final
results
shared
poster
presentation
phase
trial
patients
refractory
advanced
melanoma
phase
portion
trial
tested
safety
efficacy
increasing
doses
tilsotolimod
combination
either
ipilimumab
pembrolizumab
phase
expansion
trial
enrolled
additional
patients
recommended
phase
dose
mg
tilsotolimod
combination
treatment
regimen
evaluated
indication
company
registrational
trial
adi
diab
university
texas
md
anderson
cancer
center
delivering
presentation
part
mini
oral
session
melanoma
skin
tumors
phase
trial
evaluating
intratumoral
tilsotolimod
monotherapy
patients
refractory
solid
tumors
completed
december
final
results
presented
hani
babiker
university
arizona
cancer
center
addition
presentations
trials
abbvie
presenting
poster
phase
study
determine
safety
tolerability
pharmacokinetics
preliminary
efficacy
combinations
plus
tilsotolimod
subjects
recurrent
metastatic
head
neck
squamous
cell
carcinoma
hnscc
trial
conducted
part
clinical
research
collaboration
idera
abbvie
presentation
titles
follows
final
results
phase
trial
intratumoral
tilsotolimod
combination
ipilimumab
inhibitor
refractory
advanced
melanoma
final
results
phase
trial
intratumoral
tilsotolimod
combination
ipilimumab
inhibitor
refractory
advanced
melanoma
tilsotolimod
engages
pathway
promote
antigen
presentation
type
ifn
signaling
solid
tumors
tilsotolimod
engages
pathway
promote
antigen
presentation
type
ifn
signaling
solid
tumors
phase
trial
tilsotolimod
combination
budigalimab
patients
recurrent
metastatic
head
neck
squamous
cell
carcinoma
poster
oral
presentations
available
beginning
thursday
september
friday
september
respectively
pleased
diab
present
final
data
phase
trial
exploring
tilsotolimod
plus
ipilimumab
advanced
melanoma
patients
stated
elizabeth
tarka
idera
chief
medical
officer
looking
forward
completing
registrational
trial
indication
comparator
arm
included
moving
potential
therapy
one
step
closer
patients
idera
also
announced
company
present
wainwright
annual
global
investment
conference
tuesday
september
pm
edt
live
audio
webcast
idera
presentation
accessible
investor
relations
section
idera
website
tilsotolimod
tilsotolimod
investigational
synthetic
receptor
agonist
intratumoral
injection
tilsotolimod
shown
promote
innate
adaptive
immune
activation
tumors
active
immune
response
appear
respond
better
cpis
exclude
inhibit
immune
cells
tilsotolimod
combination
cpis
may
cause
regression
locally
injected
distant
tumor
lesions
increase
number
patients
benefit
immunotherapy
tilsotolimod
received
fast
track
designation
orphan
drug
designation
fda
evaluated
multiple
tumor
types
combination
multiple
checkpoint
costimulation
therapies
information
tilsotolimod
trials
please
visit
idera
pharmaceuticals
harnessing
approach
earliest
researchers
immunotherapy
company
vast
experience
developing
proprietary
immunology
platforms
idera
development
program
focused
priming
immune
system
play
powerful
role
fighting
cancer
ultimately
increasing
number
people
benefit
immunotherapy
idera
also
continues
focus
acquisition
development
ultimate
commercialization
drug
candidates
oncology
rare
disease
indications
characterized
small
patient
populations
serious
unmet
needs
learn
idera
visit
statements
press
release
contains
statements
within
meaning
section
securities
act
amended
section
securities
exchange
act
amended
statements
statements
historical
fact
included
incorporated
press
release
including
statements
regarding
company
strategy
future
operations
collaborations
intellectual
property
cash
resources
financial
position
future
revenues
projected
costs
prospects
clinical
trials
plans
objectives
management
statements
words
believes
expects
anticipates
estimates
plans
expects
intends
may
could
potential
likely
projects
continue
would
similar
expressions
intended
identify
statements
although
statements
contain
identifying
words
idera
guarantee
actually
achieve
plans
intentions
expectations
disclosed
statements
place
undue
reliance
company
statements
number
important
factors
could
cause
idera
actual
results
differ
materially
indicated
implied
statements
factors
may
cause
difference
include
whether
company
cash
resources
sufficient
fund
company
continuing
operations
development
company
programs
period
anticipated
whether
interim
results
clinical
trial
preliminary
results
reported
release
predictive
final
results
trial
whether
results
obtained
preclinical
studies
clinical
trials
results
described
release
indicative
results
generated
future
clinical
trials
including
clinical
trials
different
disease
indications
whether
products
based
idera
technology
advance
clinical
trial
process
anticipated
warrant
submission
regulatory
approval
whether
products
receive
approval
food
drug
administration
equivalent
foreign
regulatory
agencies
whether
company
products
receive
approval
successfully
distributed
marketed
whether
company
collaborations
successful
important
factors
set
forth
caption
risk
factors
company
annual
report
filed
form
period
ended
december
although
idera
may
elect
point
future
company
assume
obligation
update
statements
disclaims
intention
obligation
update
revise
statement
whether
result
new
information
future
events
otherwise
yervoy
ipilimumab
registered
trademark
bristol
myers
squibb
company
pembrolizumab
registered
trademark
merck
sharp
dohme
idera
pharmaceuticals
contacts
jill
conwell
investor
relations
corporate
communications
phone
john
kirby
chief
financial
officer
phone
